IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v32y2014i7p617-626.html
   My bibliography  Save this article

Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs

Author

Listed:
  • R. Diel
  • N. Lampenius

Abstract

The emergence of multi-drug-resistant tuberculosis (MDR-TB) in the European region and the high costs (nearly €536 million) generated by the nearly 72,000 notified TB cases in the EU are the factors driving the need for development and implementation of new tools against TB. In this context, cost-effectiveness analyses applying quality-adjusted life-years (QALYs) or disability-adjusted life-years (DALYs) as outcome measures for economic evaluation of improved approaches to TB control are increasingly important. While the methodology applied to derive the effectiveness data is commonly reported, less information is given regarding the derivation of utility weights in the calculation of QALYs for TB treatment. To date, despite the particular complexities of the disease, TB health effects have not been fully measured and there is no agreement on how disutility of TB disease should be accounted for. Consequently, disutility values in published studies vary considerably, and often appear to lack empirical evidence. As the need for a solid heath-economics rationale for investment in new tools against TB grows, adequate and comprehensive methods for assessing the impairments caused by different types of TB must be developed. Focusing on the assessment of DALYs as a measure of outcome in economic evaluation, we have built an exemplary model calculation applying the original TB data for Germany as reported to the Robert Koch Institute. Our work demonstrates that the use of standard equations provided in the scientific literature probably results in an underestimation of lost DALYs compared with probabilistic techniques. Providing distributions around epidemiological averages, coupled with Monte Carlo simulation to address uncertainty, may result in more realistic values. In line with a previous recommendation by the World Health Organization, it appears worthwhile to consider this more intricate approach to providing healthcare resource allocation decisions, particularly for TB. Copyright Springer International Publishing Switzerland 2014

Suggested Citation

  • R. Diel & N. Lampenius, 2014. "Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs," PharmacoEconomics, Springer, vol. 32(7), pages 617-626, July.
    • Handle: RePEc:spr:pharme:v:32:y:2014:i:7:p:617-626
    DOI: 10.1007/s40273-014-0159-5
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-014-0159-5
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40273-014-0159-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Fulgence Niyibitegeka & Montarat Thavorncharoensap & Arthorn Riewpaiboon & Sitaporn Youngkong, 2022. "Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 707-716, September.
    2. Lulua Bahrainwala & Astrid M Knoblauch & Andry Andriamiadanarivo & Mohamed Mustafa Diab & Jesse McKinney & Peter M Small & James G Kahn & Elizabeth Fair & Niaina Rakotosamimanana & Simon Grandjean Lap, 2020. "Drones and digital adherence monitoring for community-based tuberculosis control in remote Madagascar: A cost-effectiveness analysis," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-19, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:32:y:2014:i:7:p:617-626. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.